Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, Switzerland.
ChemMedChem. 2021 Mar 3;16(5):891-897. doi: 10.1002/cmdc.202000793. Epub 2020 Dec 11.
Ribosomal protein synthesis is an important target in antibacterial drug discovery. Numerous natural products have served as starting points for the development of antibiotics. We report here the total synthesis of xenocoumacin 1, a natural product that binds to 16S ribosomal RNA at a highly conserved region, as well as analogues thereof. Preliminary structure-activity relationship studies were aimed at understanding and modulating the selectivity between eukaryotic and prokaryotic ribosomes. Modifications were mainly tolerated in the aromatic region. Whole-cell activity against Gram-negative bacteria is limited by efflux and penetration, as demonstrated in genetically modified strains of E. coli. Analogues with high selectivity for eukaryotic ribosomes were identified, but it was not possible to obtain inhibitors selective for bacterial protein synthesis. Achieving high selectivity (albeit not the desired one) was thus possible despite the high homology between eukaryotic and prokaryotic ribosomes in the binding region.
核糖体蛋白合成是抗菌药物发现的一个重要靶点。许多天然产物都曾作为抗生素开发的起点。我们在此报告 xenocoumacin 1 的全合成,这是一种天然产物,可与高度保守区域的 16S 核糖体 RNA 结合,以及其类似物。初步的结构-活性关系研究旨在理解和调节真核生物和原核生物核糖体之间的选择性。在芳香区域中,修饰主要是可以耐受的。革兰氏阴性菌的全细胞活性受到外排和渗透的限制,这在大肠杆菌的基因修饰菌株中得到了证明。鉴定出了对真核核糖体具有高选择性的类似物,但无法获得对细菌蛋白质合成具有选择性的抑制剂。尽管在结合区域中真核生物和原核生物核糖体具有高度同源性,但仍有可能实现高选择性(尽管不是所需的选择性)。